# Nuvig Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuvig-therapeutics

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.nuvigtherapeutics.com
- Total disclosed funding: $61M
- Latest round: Series B (Dec 5, 2024)
- Investors on record: 14

## About

Based in California, US, and co-founded by Pamela Conley (CEO), and Greg Coffey, Nuvig Therapeutics Inc., aka Nuvig, operates as a provider of therapeutic platform that offers clinical solutions to patients dealing with diseases such as malignants and others. In May 2022, Nuvig Therapeutics Inc raised USD 47 million in series A funding co-led by new investors Novo Holdings and Platanus Ventures. In December 2024, Nuvig Therapeutics, Inc. raised USD 161 million in Series B funding co-led by Blue Owl Capital, Norwest Venture Partners, Sanofi Ventures, with participation from Abrdn, Alexandria Venture Investments, B Capital Group, Global BioAccess Fund, Leaps by Bayer, Lotte Corp., Bristol-Myers Squibb Company, Digitalis Ventures, Mission BioCapital, Novo Holdings, and Platanus Ventures.

The firm offers therapeutic medications in the form of protein, antibodies, and others for patients suffering from health issues due to immune disorders.

The company intends to use the funds raised in May 2022 for research and development of therapies that induce immunological homeostasis and treat clinical manifestations while maintaining usual immune function.

## Funding rounds

- Series B, Dec 5, 2024, $30M — Aberdeen Investments, Norwest Venture Partners, Alexandria Venture Investments, Novo Holdings, Bristol-Myers Squibb Company, Sanofi Ventures, Mission Biocapital, B Capital, Digitalis Ventures, Leaps by Bayer, Platanus Ventures, Blue Owl, Lotte Ventures, Global BioAccess Fund
- Series A, Nov 24, 2021, $31M — Novo Holdings, Bristol-Myers Squibb Company, Mission Biocapital, Digitalis Ventures, Platanus Ventures

## Investors

- Novo Holdings — Series A, Series B
- Bristol-Myers Squibb Company — Series A, Series B
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A, Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A, Series B
- Platanus Ventures (https://capitalatlas.ai/funds/platanus-ventures) — Series A, Series B
- Aberdeen Investments (https://capitalatlas.ai/funds/aberdeen-investments) — Series B
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series B
- Lotte Ventures (https://capitalatlas.ai/funds/lotte-ventures) — Series B
- Global BioAccess Fund (https://capitalatlas.ai/funds/global-bioaccess-fund) — Series B